MediAvataar's News Desk
Appoints Ashish Gupta as Director, Kaizzen Insights
Kaizzen, a leading Public Relations and Digital Media Agency, has strengthened its senior leadership team with the appointment of Ashish Gupta, as Director of Kaizzen Insights, the new research wing of the organization. Gupta will do a deep dive into issues of contemporary importance and try and figure out solutions to these complex challenges affecting the country. He will be working closely with Vineet Handa, Founder and CEO, Kaizzen.
Gupta bring with him over three decades of experience in business journalism and has worked with some of most well-known national and international newspapers and magazines including the likes of The Times of India, Indian Express, Outlook Business, Business Today and Fortune India, just to name a few.
“Ashish is highly experienced and respected business journalist with over three decades of experience in mainstream media and I welcome him to our India leadership team,” Said Vineet Handa, Founder and CEO, Kaizzen. “His deep understanding and insights of varied sectors and industries will be a great asset for Kaizzen.”
“I strongly believe that with the launch of Kaizzen Insights we will be able to transform Kaizzen into a knowledge-based and data-led communications consultancy. This will also help our existing clients in getting more informed communication and policy advocacy services.
“I am excited to join Kaizzen as Director, Insights, and hope to work with Vineet in his new endeavor to make the transformational journey a success. I hope to bring all my journalistic and other experiences to work for further growth of the company,” said Gupta.
Industry first platform interplay will witness the reality phenomenon begin on VOOT as Bigg Boss OTT, 6 weeks ahead of Season15 launch on COLORS
India’s youngest media and entertainment conglomerate, Viacom18 has constantly challenged itself through delivering innovative and category pioneering content experiences. With a vision to create a future-ready digital business, the network has been at the forefront of a digital convergence with its products and content offerings. In an industry first move, Viacom18 will now launch its marquee entertainment property, Bigg Boss, first on VOOT for 6 weeks. Christened Bigg Boss OTT, it will premiere in August 2021 with unprecedented access, engagement, and interactivity empowering viewers to immerse themselves in the journey of contestants in the Bigg Boss house. In addition to the 1-hour episode on VOOT, viewers will get a chance to watch exclusive cuts, round the clock content drops and a fully interactive 24*7 LIVE feed from the house. After the completion of the digital exclusive, the show will move seamlessly into COLORS with the launch of Season15 of Bigg Boss.
Recognized as the biggest entertainment property of Indian television, Bigg Boss has stamped its pull even in the hyper-competitive digital entertainment space. With over 8.5 Billion views, the show has dominated the digital space with a whopping 92 percent share-of-voice. Unleashing its fandom and immense consumption power on digital, Bigg Boss has garnered significant patronage of brands and advertisers who continue to engage with the iconic property, season after season, making it India’s leading entertainment property – both on television and digital.
Speaking about the launch of Bigg Boss first on VOOT, Gourav Rakshit, Chief Operating Officer, Viacom18 Digital Ventures, said, “VOOT has grown to become home to entertainment in India through industry leading engagement and shareworthy content across originals, international, catchup and content-around-content segments. The launch of Bigg Boss OTT exclusively on VOOT before TV is poised to be yet another game changer in digital entertainment and a step forward in further cementing our position as the most loved consumer entertainment brand. This season is set to empower our audiences through unparalleled category defining innovation through interactivity which we are sure will provide significant to our users, advertisers and brands alike.”
While explaining the content strategy behind Bigg Boss OTT, Manisha Sharma, Chief Content Officer, Hindi Mass Entertainment, Viacom18, said, “Bigg Boss, over the years, has grown to become a phenomenon that drives conversations across the country. With the launch of Bigg Boss OTT, our digital audiences are in for a treat. The new digital exclusive format will take the show’s fandom to its next level through active engagement with viewers being able to play a part in the show’s progress. The beauty of this show lies in the versatility of format and the massive popularity it commands – both aspects helping us in customizing the show as two different content offerings for the two different platforms while maintaining its core ethos.”
With the aim to build an increasingly symbiotic content ecosystem for the network, for the first time in the history of Indian entertainment, the country’s biggest broadcast GEC show will launch first on digital. Starting August 2021, Bigg Boss will go live first on VOOT and after 6 weeks of exclusive streaming on digital, the show will launch in a fresh avatar in its 15th Season on COLORS.
Promising to be packed with ultimate over the top excitement and thrill, Bigg Boss OTT will set a milestone on digital through its disruptive content strategy. Tune in to watch Bigg Boss OTT as a digital exclusive only on VOOT starting from August, 2021.
Tune into Colors Tamil on Sunday 11th July, at 1:00 PM and 3:30 PM, to watch Velvet Nagaram and Nayyapudai
Colors Tamil, the youngest GEC of Tamil Nadu, is all set to excite its viewers with back to back World Television Premieres of two blockbuster movies this weekend. As part of its popular Sunday Cine Combo, the channel aims to get your day off to a great start with Nayyapudai, an action thriller, directed by Vijaya Kiran. It follows it up with Velvet Nagaram, a gripping tale about an investigative journalist. Tune in to Colors Tamil, this Sunday, 11th July 2021, at 1:00 PM and 3:30 PM to watch the two spine-tingling hits.
Nayyapudai’s storyline follows the fights of a retired army officer against corruption, and his role in saving a couple from the clutches of a local don. Essayed by veteran Director S.A. Chandrasekharan, the character Vellaichamy is a charitable man who takes care of children from impoverished families. His quaint life takes an unexpected turn as he gives refuge to a couple, played by Pa Vijay and Chandini Tamilarasan, who have eloped.
Velvet Nagaram is a psychological thriller starring Varalaxmi Sarathkumar and Ramesh Thilak, and directed by debutant Manoj Kumar Natrajan. The film is based on real-life incidents and revolves around a journalist who traces the mystery behind the murder of an actress but finds herself in a dangerous situation after getting cornered by a bunch of goons. The film has realistic performances and many tense moments. It also boasts of mind-blowing cinematography by Bagath Kumar. With music composed by Achu Rajamani, (known for his album Goli Soda), it promises to be an edge of the seat ride for the audience.
Don't forget to tune in to Colors Tamil this Sunday, 11th July at 1:00 PM and 3:30 PM, for a riveting weekend. Colors Tamil is available on all leading cable networks and DTH platforms - Sun Direct (CH NO 128), Tata Sky (CHN NO 1515), Airtel (CHN NO 763), Dish TV (CHN NO 1808) and Videocon D2H (CHN NO 553).
Viewers can also tune in to VOOT any time to see Colors Tamil shows at their convenience.
Announcement comes as Reuters Institute Digital Report shows BBC as India’s most trusted international news brand
Ipsos Affluent survey highlights BBC is one of the top three online news brands in India
Comscore recently revealed BBC sites in India have recorded highest ever UVs
The latest statistics from multiple studies indicates that BBC News outperforming most news brands in India on a number of different metrics. As per the Reuters Institute Digital News Report 2021, BBC News in India reaches more people weekly: holding the third highest weekly usage online and it’s in top five amongst the TV, radio and print category. Audiences in India are now turning to trusted brands and BBC News is one of the top four leading news brands.
New data from Ipsos shows BBC is one of the top three online news brands among India’s Affluent. In the television news channels category, BBC World News is in the top five news channels among India’s Affluent and is the fastest growing international news channel.
Demand for BBC News’ output from audiences around the world in different segments has hit record highs recently, as readers and viewers seek trustworthy, independent and objective coverage of world changing events.
Rahul Sood, Managing Director of BBC Global News India, said: “More audiences are turning to the BBC as they want to rely on the information given by a trustworthy source. The past year has shown how disinformation is spreading online to millions of people. Fake news has a detrimental effect on people’s lives, and it is vital that audiences know they can turn to sources, such as the BBC, for accurate, impartial information.”
Rupa Jha, BBC Head of Indian Languages, said: “The BBC offers a uniquely objective brand of news, which gives audiences the facts so they can make informed decisions about the issues that really matter. The rigorous verification process at the BBC is core to our editorial values and principles of accuracy and impartiality, and every story is authenticated before it’s broadcast.”
Also, independent data from Similarweb has revealed that the BBC is once again, the world’s most visited news site amongst traditional news publishers.
Separate research* shows that the BBC is still considered the world’s most trusted and reliable international news broadcaster.
BBC.com registered record traffic in May 2021 in India, recording 44 million pageviews with 32% year over year growth.
BBC sites (consisting of all BBC sites visited by Indian audience) registered 52.5 million unique visitors in India in March 2021, the highest ever.
GPC Tops Ranking of Traditional Chinese Medicine Brands
Sinopharm tops ranking of most valuable Chinese pharma brands, brand value US$3.2 billion
GPC claims title of second most valuable Chinese pharma brand and top spot in sub ranking of top 5 most valuable traditional Chinese medicine brands, brand value US$1.5 billion
SPH completes podium with its commitment to R&D paying off
Brand Finance conducted original market research on perceptions of Chinese pharma brands, surveying opinions of 1,000 respondents aged 18-75 across nation
Overall consumer perceptions of Chinese pharma brands are largely positive: brands scored well for quality and respondents in general think Chinese pharma brands care more about customers than profits
Yunnan Baiyao is strongest Chinese pharma brand with AA brand strength rating
Sinopharm, Tong Ren Tang, 999, and GPC round off top 5 for brand strength
Leading the fight against the nation’s health emergency, Chinese pharma brands have performed extremely well over the previous year. According to the Brand Finance China 500 2021 ranking, the pharma sector recorded an impressive 123% cumulative brand value increase – a result bolstered by solid performances across the board, as well as from the eight new brands that entered the ranking this year. Furthermore, four of these brands feature in the Brand Finance Pharma 25 2021 ranking – a ranking of the world’s top 25 most valuable and strongest pharma brands - Sinopharm, Guangzhou Pharmaceuticals Corporation, SPH and, Yunnan Baiyao.
Now, for the first time Brand Finance has ranked the top 15 most valuable and strongest Chinese pharma brands.
Scott Chen, Managing Director, Brand Finance China, commented:“There is no denying the importance of the role of Chinese pharma brands over the previous year as they spearheaded the fight against the nation’s health emergency and their operations were propelled to the centre of society like never before. This newly-released ranking of the top 15 most valuable and strongest Chinese pharma brands demonstrates the true strength of the sector, with extremely positive results recorded across the board.”
Vaccine development reaps benefits for Sinopharm
Topping the new ranking of China’s most valuable pharma brands is Sinopharm, which has recorded a 58% brand value increase to US$3.2 billion. Sinopharm is making major strides in the global race to produce COVID-19 vaccinations and has since developed a vaccine with a high efficacy rate, which has already been distributed to millions worldwide.
GPC sits in 2nd
Sitting in second is Guangzhou Pharmaceuticals Corporation, boasting a 74% increase in brand value to US$1.5 billion. GPC - one of China’s largest drug makers – has recently entered a partnership with PepsiCo to jointly develop healthy oatmeal products. Furthermore, as one of the top Chinese medicine manufacturers, GPC has been making significant developments by contributing its knowledge of the traditional Chinese medicine – Banlangen – towards controlling the pandemic.
SPH completes podium
Completing the podium in 3rd spot is SPH (brand value up 50% to US$1.4 billion). The brand prides itself on being a leader for research and development across the industry, spending US$194.9 million on research in 2019 alone.
SPH has placed itself in a strong position to reap the rewards of the pandemic-induced shift away from traditional healthcare towards the online and technological side of the sector, through recently securing funding for its online prescription and pharmacy businesses. This funding will also allow the brand to consolidate its network of hospital-centred Chinese pharmacies.
Top 5 traditional Chinese medicine brands
GPC is most valuable traditional Chinese medicine brand
Brand Finance has also created a sub ranking from the Chinese pharma ranking for traditional Chinese medicines brands, given their rise in popularity in recent years.
GPC claims the top spot in this ranking, with Yunnan Baiyao sitting in 2nd. 999 claims third position, following a 50% brand value increase to US$243 million. 999 has recently entered a partnership with insurance giant Ping An, enabling users to directly enjoy 999 Ganmaoling Granules through the Ping An Health app.
Tasly (brand value US$228 million) and Tong Ren Tang (brand value US$207 million) round off the top 5 in 4th and 5th positions, respectively. Tasly continues to focus heavily on R&D and innovation across its operations - the company currently has 75 research projects, 38 category 1 innovative drugs, as well as 46 that have entered the clinical research stage.
Yunnan Baiyao is the strongest Chinese pharma brand
In addition to measuring overall brand value, Brand Finance also determines the relative strength of brands through a balanced scorecard of metrics evaluating marketing investment, stakeholder equity, and business performance.
Brand Finance also conducted original market research on the Chinese pharma sector, where 1000 respondents were asked about the 15 Chinese pharma brands that feature in the ranking and their opinions on a variety of metrics including reputation, recommendation, and trust.
Results from the market research directly funnel into the Brand Strength Index and therefore the responses impact how brands perform in terms of brand strength.
Yunnan Baiyao is the strongest Chinese pharma brand with a Brand Strength Index (BSI) score of 73.2 out of 100 and a corresponding AA brand strength rating. Sinopharm (BSI 69.1), Tong Ren Tang (BSI 68.9), 999 (BSI 67.4) and GPC (BSI 66.0) round off the top 5 for brand strength.
Overall, brands scored well and generally received high scores for quality. Yunnan Baiyao and Tong Ren Tang ranked first, both scoring 4.2 out of 5, followed by GPC and Baiyunshan scoring 4.0 out of 5. Some consumers have complained, however, about Tong Ren Tang using its brand to increase profits, by developing and selling irrelevant products, which may bring complications to its branded products in the future.
In general, respondents from the older age group tend to give higher quality scores to brands, compared with the lower two age categories. This is not the case for Sinopharm, which has higher quality perceptions (4.0/5.0) among the younger age group of respondents (18-34), a score higher than the mid-age group (35-54)’s perceptions at 3.9 and the older age group (55-75)’s result at 3.8. This is potentially the result of the younger generation having more trust in the COVID-19 vaccination than their older counterparts.
Humanwell performs strongly in the 18-34 age group (7.0/10) compared with the two older age groups (35-54 and 55-75), scoring 6.3 and 6.8 out 10, respectively. This is predominantly due to the popularity of its women’s health products, as a leading brand in fertility space.
Genuinely offer something different
Yunnan Baiyao and Joincare pharma rank first in this measure due to their unique product offering in the market. For example, Baiyao series products are exclusive to Yunnan Baiyao and the formula remains a nationwide top secret. Its core variations have been selected into the National Medical Insurance Class A drug catalogue for many years.
Positive perceptions around profits versus costumer well-being
Respondents in general do not think that Chinese pharma brands care more about profits than their customers. This is largely due to the medicine regulation in China, as well as the increasing availability of public health insurance.
Good product range
The top three pharma brands - Sinopharm, SPH and GPC rank top in this measure, with scores of 49%, 51%, and 44% respectively. GPC also benefits from producing both Western medicine and traditional Chinese medicine, unlike the other two which largely focus on Western medicine.
Awareness: Yunnan Baiyao leads, scoring impressive 97% across all age groups
Yunnan Baiyao boasts the highest awareness score (97%) across all three age groups, followed by Tong Ren Tang (94%). Humanwell performs worst (23%) among all three age groups.
The three biggest pharma groups researched - Sinopharm, SPH, and GPC - scored 85%, 56%, and 63% respectively. Sinopharm’s contribution to the Covid vaccine race has propelled it to become a household name across the nation.
Some brands, such as CSPC, have a strong regional focus and presence. It scored 79% in Jinan and 72% in Beijing in northern China, but did not perform well in the southern provinces. The same trend is witnessed with Tasly. Trends like this are often the result of brands simply not reaching awareness levels on a national scale yet and therefore they naturally fall behind the sector leaders Sinopharm, SPH, and GPC in this metric.
Familiarity: Once again Yunnan Baiyao leads pack
The familiarity metric follows a similar trend to the awareness metric, with Yunnan Baiyao ranking first (67%) among all three-age group respondents, followed by Tong Ren Tang (63%). Sinopharm and Bai Yun Shan also perform well, scoring 45% and 41% respectively.
Humanwell Healthcare, Tasly, and Joincare Pharma score the lowest – ranging from a 5% to 10% familiarity level, largely a result of their limited consumer-facing branded product range.
Consideration: Yunnan Baiyao and Tong Ren Tang score 99% and 98% respectively
Among those who are familiar with the Yunnan Baiyao and Tong Ren Tang brands, 99% and 98% would consider choosing to use their products. Sinopharm, SPH, 999, Harbin Pharmaceutical, and GPC also boast high consideration scores (all over 90%).
GPC own products that consumers use in their everyday lives – such as Wanglaoji and Banlangen granules – therefore earning them a high consideration score. GPC is also the largest manufacturer in China for digestible antibiotics, owning the first brand of digestible antibiotics, Kangzhiba. Furthermore, its leading product cefathiamidine is currently the only cephalosporin developed by the Chinese themselves.
Reputation Versus Recommendation
GPC scores 7.7. Brands within the GPC group including Chenliji and Wanglaoji have a long history and products from these brands including Banlangeng and xiaocaihu granules have played an important role in fighting the pandemic, therefore contributing to the strong reputation score.
The average score in the traditional Chinese medicine group is 7.8, which is higher than the Western medicine group at 7.5, demonstrating that generally traditional medicine has a higher reputation due to its history and culture accumulation.
Sinopharm ranks top in the Western medicine group with a score of 8.0. Sinopharm owns over 1,100 subsidiaries as well as six listed companies and has built a nationwide logistic and distributing network for providing quality service to more than 230,000 corporate clients.
Yunnan Baiyao and Tong Ren Tang rank joint first with a score of 8.3 out of 10. GPC also boasts a high recommendation score of 7.8. Ten traditional Chinese medicines from the GPC group were selected for use in the diagnosis and treatment of Covid by the government, showcasing strong endorsement of GPC products.
Sinopharm and Fosun Pharma are the only two brands with a recommendation score higher than 8 out of 10 in the Western medicine group. Fosun Pharma has recently won a new partnership with BioNTech – German biotechnology company behind the globally known Pfizer–BioNTech Covid vaccine - and is commercialising its mRNA technology in producing vaccine products across China.
Buchang Pharma surprisingly performs best among the 18-34 age group with a score of 8.5 for recommendation. The company is focusing on the modernisation of traditional Chinese medicine, explaining its popularity among the younger age category.